Key Summary Points {#FPar1}
==================

This review provides a summary of the distinct features of lobular breast cancer and how these impact current clinical decision-makingAn overview of the key diagnostic, surgical and medical therapy challenges in lobular breast cancer is presentedKey clinical trials of targeted and immunomodulatory therapies in lobular breast cancer are outlinedThe article emphasises the functional implications of lobular breast cancer's unique molecular biology and their potential impact on therapy in the future

Introduction {#Sec1}
============

Invasive lobular breast cancer (ILC) accounts for 10--15% of all breast cancers making it the second most common type of breast cancer behind invasive ductal carcinoma (IDC, also known as invasive carcinoma of no special type) \[[@CR1]--[@CR4]\]. There has been an apparent increase in the incidence of ILC over the last 2 decades due to diagnostic advances \[[@CR5], [@CR6]\]. Increased incidence of ILC is associated with the use of hormone replacement therapy in postmenopausal patients \[[@CR7]--[@CR9]\]. Compared with IDC, ILC tends to occur in older women \[[@CR10]\].

Many studies show that ILC is associated with a good prognostic phenotype, i.e., well-differentiated (low grade), low-to-moderate proliferation index, hormone receptor positivity for both oestrogen receptor-α (ER) and progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2)-negativity and basal marker negative status \[[@CR11], [@CR12]\]. Although the majority of ILC is ER-positive and responds well to endocrine therapy, retrospective clinical cohort studies show that long-term outcomes of ILC are equivalent or even inferior to that of IDC \[[@CR13]--[@CR15]\]. However, the evidence is mixed and there are conflicting data to suggest that adjusting for stage would abolish any difference in long-term clinical outcome between ILC and IDC \[[@CR16]\]. This highlights the need for further research into the biological basis of observed differences between ILC and IDC, coupled with prospective clinical trials aimed at improving outcomes for patients with ILC.

This article summarises the morphological and molecular features of ILC at presentation and how these affect the diagnosis and management of ILC. Current management strategy, key clinical trials and future directions as a result of functional study of the consequences of its unique molecular profile are discussed in this article.

Discussion {#Sec2}
==========

Histopathological and Molecular Characteristics of Lobular Breast Cancer {#Sec3}
------------------------------------------------------------------------

Most ILC is classified as luminal A in terms of its molecular subtype: ER positive, PR positive, low proliferation index (Ki67) and HER2 negative \[[@CR11], [@CR12]\]. In ILC, the basal subtype (triple negative: ER, PR and HER2 negative) occurs less frequently and is linked to a distinct "pleomorphic" histological subtype. Classic ILC is made up of uniform cells with spherical nuclei and indistinct nucleoli, whereas pleomorphic ILC tends to consist of larger cells with expansive eosinophilic cytoplasm \[[@CR17]\].

The classic hallmark of ILC, found in 85--95% of cases, is loss of E-cadherin protein expression, which leads to its distinctive discohesive appearance and characteristic single-file pattern of invasive cells (see Fig. [1](#Fig1){ref-type="fig"}) \[[@CR11], [@CR18], [@CR19]\]. E-cadherin is a calcium-dependent transmembrane protein that mediates intercellular adhesion and polarity by homophilic attachment to adjacent cells; thus, loss of E-cadherin results in loss of intercellular adhesion with detached cells undergoing programmed cell death by anoikis \[[@CR18], [@CR20]--[@CR22]\].Fig. 1Comparison of key molecular and histological features of ILC and IDC and the implications for treatment of ILC. E2 = oestradiol; PTEN/Akt refers to PTEN loss and Akt activation; ER programme refers to the distinct ER-mediated gene expression programme in ILC.Adapted with permission from Ciriello et al. \[[@CR12]\]

Mechanisms of E-cadherin loss in ILC include mutation or methylation of the *CDH1* gene (located at chromosome 16q22.1) and loss of heterozygosity in the chromosome region 16q \[[@CR23]--[@CR25]\]. Another mechanism of E-cadherin loss is dysregulated expression of catenin-binding proteins (α, β, γ and p120-catenin), which anchor E-cadherin to the membrane and the actin cytoskeleton \[[@CR26], [@CR27]\]. Downregulation of catenin-binding protein (CBP) leads to its cytoplasmic redistribution and makes ILC cells resistant to anoikis. CBP downregulation also leads to activated Rho/Rock signalling, which promotes cell migration \[[@CR22], [@CR26], [@CR27]\]. These observations suggest that CBP downregulation enables ILC cells to survive and proliferate in their characteristic single-file pattern.

Loss of functional E-cadherin may be associated with epithelial-to-mesenchymal transition (EMT), although this remains controversial. Cadherin switching in *CDH1*-deficient tumours to N-cadherin may favour a mesenchymal phenotype. However, since E-cadherin loss in ILC tends to be an early event, the association of EMT with later stages of cancer progression suggests that E-cadherin loss is not sufficient to cause EMT. This topic has been extensively described by McCart Reed and colleagues \[[@CR11], [@CR28]\].

Besides E-cadherin loss, ILC is enriched versus IDC for inactivating phosphatase and tensin homologue (*PTEN*) alterations (14% vs. 3%), forkhead box protein A1 (*FOXA1*) mutations (7% vs. 2%) and runt-related transcription factor 1 (*RUNX1*) mutations (10% vs. 3%) \[[@CR12]\]. Loss of the tumour suppressor, PTEN, as a result of homozygous chromosomal loss at 10q23, is associated with increased Akt phosphorylation, which is strongly activated in ILC, upregulates EGFR and thus creates a more aggressive phenotype \[[@CR12], [@CR29]--[@CR31]\]. Along with enrichment of *FOXA1* mutation, ILC is distinguished from IDC by relatively low frequency of *GATA3* mutations (5% vs. 20%) \[[@CR12]\]. FOXA1 and GATA3 are key transcriptional regulators of ER activity \[[@CR32], [@CR33]\]. These findings suggest critical and mutually exclusive roles for FOXA1 and GATA3 in the evolution of ILC and IDC, respectively.

FoxA1 is a pioneer transcriptional factor that opens condensed chromatin to allow ER to bind at specific sites on the DNA, thereby inducing cell cycle progression and tumour growth \[[@CR32], [@CR34]\]. *FOXA1* is a component of a gene expression signature associated with luminal breast tumours, which is associated with a better prognosis \[[@CR35]\]. *FOXA1* mutations in ILC cluster in the forkhead (DNA-binding) domain \[[@CR12], [@CR36]\]. This implies that mutations may affect the pioneer function of FoxA1 and thereby alter ligand-dependent ER binding to DNA. *FOXA1* mutations may therefore alter the response to ER-targeted therapies such as tamoxifen, a selective ER modulator. For example, forkhead box mutations in *FOXA1* may alter the avidity of FoxA1 binding to DNA at specific genome loci, thereby reprogramming genomic ER binding and leading to altered gene expression profiles associated with proliferation and/or endocrine resistance \[[@CR36]\]. These hypotheses warrant urgent preclinical and clinical investigation.

Diagnosis of Lobular Breast Cancer {#Sec4}
----------------------------------

ILC does not always present with a firm lump in the breast and therefore poses particular challenges for its detection clinically and/or via screening \[[@CR37]\]. Signs of ILC may include a thickened or swollen area in the breast with or without a change in the nipple shape (e.g., inverted nipple) and dimpling of the skin \[[@CR38]\]. Relative to other subtypes of breast cancer, the extent of a primary ILC lesion is difficult to assess both clinically and by mammography because of its infiltrative growth pattern into the stroma without desmoplastic reaction \[[@CR38], [@CR39]\].

Due to its diffuse and discohesive ILC morphology, ILC cannot be accurately assessed by mammography alone \[[@CR40]\]. Sensitivity of mammography for ILC ranges from 57 to 81% \[[@CR40], [@CR41]\]. Furthermore, whilst magnetic resonance imaging (MRI) offers improved resolution, studies suggest that the ability of MRI to assess suitability for breast-conserving surgery is often suboptimal in cases of ILC \[[@CR42]\]. In addition, compared with other subtypes, there is evidence that synchronous contralateral (i.e., bilateral) primary disease occurs more frequently in ILC (20.9% in ILC versus 11.2% in IDC; *p* \< 0.0001) \[[@CR43]\].

Late-presenting ILC has a distinct profile of distant metastatic sites. In ILC, transcoelemic spread leads to relative increase in frequency of gastrointestinal tract, peritoneal and ovarian metastases \[[@CR13], [@CR43], [@CR44]\]. ILC that has spread to the gastrointestinal tract may present with gastrointestinal upset and bowel symptoms, including subacute and acute obstruction, while peritoneal disease may present with ascites, hydronephrosis and/or hydroureter. In terms of the 'classic' sites of breast cancer metastases, there is relatively more metastasis to bone and skin and less to lungs and brain \[[@CR43], [@CR44]\]. In patients on adjuvant therapy for ILC, or those being followed up post-adjuvant therapy, knowing the histological subtype is crucial in predicting the spread and monitoring for recurrence.

Current Treatment of Primary Lobular Breast Cancer {#Sec5}
--------------------------------------------------

Current treatment for ILC follows identical treatment protocols as for all other histological subtypes of breast cancer \[[@CR45]\]. This section focuses on how known ILC-specific features may impact surgical and medical management (i.e., endocrine therapy and chemotherapy). Emerging therapy modalities such as immunomodulation---already a mainstay of treatment in advanced breast cancer---are likely to have an impact on primary treatment protocols in the near future \[[@CR46]\]. Immunotherapy is discussed further in "[Future Treatment of Lobular Breast Cancer](#Sec9){ref-type="sec"}").

### Surgery {#Sec6}

In most cases of breast cancer, breast-conserving surgery by wide local excision is performed to remove the tumour with a margin of the surrounding normal tissue \[[@CR45]\]. However, in ILC, there is evidence that 17--65% of patients have to undergo a second surgical intervention \[[@CR47]\]. This raises concerns about the accuracy of ILC assessment due to its diffuse and multifocal morphology. Consequently, patients with ILC are more likely to undergo breast removal by mastectomy. Whilst offering greater resolution, MRI scanning may also increase false-positive detection of regional disease leading to an inappropriate increase in rates of mastectomy \[[@CR42]\]. Following surgery, patients with ILC often undergo contralateral mastectomy because of the known tendency for bilateral ILC to occur \[[@CR48]\].

Despite concerns regarding the uncertainty of complete excision of primary ILC following breast-conserving surgery, evidence suggests that modern surgical approaches confer the same rates of local recurrence for ILC, IDC and mixed histology tumours \[[@CR49]\]. Furthermore, evidence shows that mastectomy may not offer a long-term survival advantage over breast-conserving surgery \[[@CR50]\]. These observations imply that the rate of breast-conserving surgery in ILC could be increased without compromising long-term clinical outcomes.

### Neoadjuvant Therapy {#Sec7}

Besides initial surgery, there is an option to have primary systemic treatment to manage ILC \[[@CR45], [@CR51]\]. Neoadjuvant chemotherapy is aimed at improving rates of breast-conserving surgery. However, consensus has emerged that ILC tends to respond poorly to chemotherapy, leading to lower disease-free and overall survival following neoadjuvant chemotherapy compared with IDC \[[@CR52]--[@CR54]\]. Histological evidence indicates that ILC persists in up to 99% of cases (i.e., only 1% rate of pathological complete response) following anthracycline-based neoadjuvant chemotherapy \[[@CR55]\]. The poor response to chemotherapy is also associated with its luminal A subtype (ER/PR positive, low mitotic index/Ki67) \[[@CR53]\]. Neoadjuvant chemotherapy is generally not considered for patients with ILC as it is unlikely to improve rates of breast-conserving surgery but exposes patients to toxicities that can be life threatening.

As most ILC is luminal A type and hormone responsive, treatment with endocrine therapy in the neoadjuvant setting may be preferable to chemotherapy. A retrospective study of 61 patients with ER-positive ILC found that neoadjuvant letrozole reduced tumour size by a mean of 66% at 3 months, and the rate of successful breast conservation was 81% \[[@CR56]\]. This small study demonstrates that there is untapped potential to increase rates of breast-conserving surgery and reduce rates of mastectomy in ILC---especially as endocrine therapy is optimised by combination with targeted therapies such as CDK4/6 inhibitors. Specific targeted therapies in ILC are discussed further in "[Future Treatment of Lobular Breast Cancer](#Sec9){ref-type="sec"}".

### Adjuvant Therapy {#Sec8}

Post-surgery, depending on prognostic risk factors and biomarker expression, patients may need to undergo adjuvant radiotherapy, chemotherapy and/or endocrine therapy \[[@CR45]\]. In high-risk cases of primary disease in which patients receive adjuvant chemotherapy, there is evidence that ILC has an inferior prognosis than IDC, even after correcting for confounding factors such as patient age and breast cancer stage \[[@CR13]\]. This is corroborated by studies showing that taxane-based chemotherapy is less effective in patients with hormone receptor positive, low proliferation and/or lobular histologic subtype tumours \[[@CR57], [@CR58]\]. On the other hand, studies have consistently shown that ILC responds well to endocrine therapy. In the adjuvant setting, tamoxifen, a selective ER modulator, is indicated for pre-menopausal women, whilst post-menopausal women are given a third-generation aromatase inhibitor such as anastrozole or letrozole, irrespective of the histological subtype of breast cancer (see \[[@CR59]\] for a recent review).

There is retrospective clinical evidence that patients with ILC benefit less from adjuvant tamoxifen than patients with IDC (see Fig. [2](#Fig2){ref-type="fig"}). At 8 years of follow-up, disease-free survival on adjuvant tamoxifen was 66% for patients with ILC versus 75% for patients with IDC (*p* = 0.03) \[[@CR60]\]. In contrast, benefit from adjuvant letrozole at 8 years was identical between ILC and IDC (82% disease-free survival for both). This implies an intrinsic resistance to tamoxifen in ILC and that patients with ILC should be preferentially offered adjuvant aromatase inhibition. A current pre-surgery window-of-opportunity study (Clinical Trials registration no. NCT02206984) is investigating which ER-targeted therapy (fulvestrant vs. anastrozole vs. tamoxifen) is most effective in ILC \[[@CR61]\]. With sufficient recruitment, this study could indicate which endocrine therapy agent gives the strongest signal of response in ILC.Fig. 2Retrospective clinical evidence of a differential response to different classes of endocrine therapy in ILC. These data formed the basis of in vitro functional and early clinical studies of the differences between ILC and IDC. Kaplan-Meier plots show **a** disease-free survival and **b** overall survival stratified by histology (ductal/lobular) and endocrine therapy agent (letrozole, L/tamoxifen, T); *N* = 2923.Reproduced with permission from Metzger Filho et al. \[[@CR60]\]

There is evidence that adjuvant radiotherapy improves survival outcomes for patients with ILC \[[@CR62]--[@CR64]\]. However, relatively few studies have investigated radiotherapy in the specific context of ILC, and further study is urgently required.

Future Treatment of Lobular Breast Cancer {#Sec9}
-----------------------------------------

In the future, the treatment of ILC may be improved with better understanding and clinical application of its unique molecular profile. For example, there is evidence that amplification of fibroblast growth factor receptor 1 (*FGFR1*) is a feature specific to ILC \[[@CR65], [@CR66]\]. A study by Sikora et al. found that the ILC cell line model, MM134, is intrinsically resistant to tamoxifen and provided evidence that this could be reversed by inhibition of FGFR1 \[[@CR65]\]. The same in vitro study demonstrated that in ILC, ER drives a unique gene expression program associated with resistance to tamoxifen. Subsequently, the group showed that *WNT4* (encoding a Wnt signalling pathway ligand) was the most strongly upregulated ER target gene in ILC and may represent a novel therapeutic target to enhance response to endocrine therapy in patients with ILC \[[@CR67]\].

Acquired mutations in *ESR1* are found in 5--25% of secondary breast tumours as a result of selective treatment pressure leading to constitutive ER activity \[[@CR68]--[@CR71]\]. Whilst *ESR1* mutations are relevant to the choice of therapy in metastatic breast cancer (for example, using an ER downregulator, i.e., fulvestrant), there is no evidence that specific *ESR1* mutations pre-exist in primary ILC \[[@CR72]\]. However, the unique ER-mediated gene expression programme in primary ILC leads to the hypothesis that alteration of ER transcriptional regulators---e.g., DNA binding domain mutations in *FOXA1* and *RUNX1*---may link to endocrine resistance and clinical outcomes in an ILC-dependent manner. As a potential target in endocrine-resistant breast cancer, FoxA1 is therefore a promising future therapeutic research area for ILC \[[@CR73]--[@CR75]\]. Traditionally, transcription factors have been considered therapeutically intractable, although ligand-activated nuclear receptors such as ER are the classic counterexample.

Cyclin-dependent kinase (CDK) 4/6 inhibitors, e.g., palbociclib and ribociclib, are licensed first line in advanced ER-positive, HER2-negative breast cancer in combination with endocrine therapy \[[@CR76], [@CR77]\]. Multiple clinical trials are investigating the use of CDK4/6 inhibitors in the neoadjuvant and adjuvant settings for ER-positive breast cancer. To better understand how ILC might respond to neoadjuvant CDK4/6 inhibition, the Palbociclib and Endocrine Therapy for Lobular Breast Cancer Preoperative Study (PELOPS, Clinical Trials registration no. NCT02764541) is measuring the pathological complete response rate after 24 weeks of endocrine therapy with or without palbociclib \[[@CR78]\]. Given the relative lack of chemotherapy response in ILC, this neoadjuvant trial (expected to complete in 2020) is potentially pivotal for patients with ILC. The trial design also incorporates a window-of-opportunity phase to test the hypothesis that letrozole is more effective in ILC than tamoxifen (see Fig. [3](#Fig3){ref-type="fig"}) \[[@CR78]\].Fig. 3PELOPS trial of neoadjuvant palbociclib, including a window-of-opportunity phase to provide prospective evidence on endocrine therapy of choice in ILC \[[@CR78]\]. Study population is enriched for ILC. Treatment with palbociclib is randomly allocated. Primary outcome measure is complete pathological response

Other strategies under clinical investigation for ILC include ROS1 targeting with crizotinib in advanced E-cadherin-negative, ER-positive lobular breast cancer and diffuse gastric cancer, known as the ROLO study (Clinical Trials registration no. NCT03620643) \[[@CR79]\]. This trial exploits a synthetic lethality between E-cadherin deficiency and inhibition of the tyrosine kinase ROS1 \[[@CR80]\]. Crizotinib is an existing ROS1 tyrosine kinase inhibitor licensed for use in ROS1-positive non-small-cell lung cancer that could in theory be repurposed for E-cadherin-deficient cancers. If positive response rates are seen in advanced ILC, this approach may lead to further trials investigating ROS1 inhibition in the adjuvant or neoadjuvant settings.

Recent evidence suggests that immune-related gene expression defines some ILC subtypes and is associated with survival rate \[[@CR12], [@CR81]\]. Compared with IDC, there is evidence that ILC exhibits higher activity of almost all types of immune cells \[[@CR81]\]. In this study by Du et al., evidence of lymphocytic infiltration in ILC tumours is linked to neoadjuvant chemotherapy response. However, a study by Desmedt et al. shows that even though lymphocyte infiltration is present in ILC, it is 21% lower than in IDC (*p* \< 0.001) \[[@CR82]\]. In ILC, high lymphocyte infiltration is associated with highly proliferative tumours, suggesting that there is a subgroup of ILC likely to respond well to existing immune checkpoint (PD-1, PD-L1 and CTLA4) inhibitors \[[@CR82]\].

Response of ILC tumours to immune checkpoint inhibition is currently being investigated in a phase 2 clinical trial assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer (the GELATO study, Clinical Trials registration no. NCT03147040) \[[@CR83]\]. Atezolizumab is a monoclonal antibody targeting programmed death ligand 1 (PD-L1). Its mechanism of action is to disrupt the T cell inhibitory interaction of PD-L1 (on antigen-presenting cells) with its receptor PD-1 (on T-cells), thereby "taking the brakes off" the immune response. The study also aims to find novel markers of response to carboplatin plus atezolizumab, which could be very informative for future trials of immunotherapy in ILC.

Conclusion {#Sec10}
==========

ILC has distinct morphological features that relate to key molecular hallmarks such as loss of E-cadherin, which can make diagnosis and surgical treatment more challenging compared with IDC. On the other hand, ILC is characterised by molecular features such as ER and PR positivity that are associated with good clinical outcome and response to endocrine therapy.

The challenge for the field remains to improve our understanding of the functional implications of the unique molecular profile of ILC, beyond loss of E-cadherin. Linking ILC-associated molecular features with clinical phenotype---including response to endocrine therapy---and developing novel therapeutic strategies for biomarker-led and immunomodulatory clinical trials will be key to improving long-term outcomes for patients with ILC.
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